Navigation Links
NTI in Biological Technology

Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition

...l be presented at the MSC Booth (#1951) during the nti Critical Care Exposition, May 19-21, with opportunities for all nti attendees to participate in both types of simulati..., including training options, will be available at nti and can also be found online at www.medsimulatio...

Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company

...result in a transaction that meets our objectives, nti will act expeditiously to return as much cash as p...potential new drug to treat acute ischemic stroke. nti has recently chosen not to extend its early-stage ...a collaborative agreement with the Buck Institute. nti has rights to receive payments from an approved dr...

Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results

...ed product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. nti has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an inves...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

... treatment of Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine...inical trials for evaluation as a new drug to treat acute ischemic stroke. nti has an early-stage development program for Alzheimer's disease and rights t...

Neurobiological Technologies Announces Suspension of Viprinex Development

...mum necessary to carry out operations and complete contractual obligations. nti is terminating a majority of its employees this week, with additional emplo...linical trials for evaluation as a new drug to treat acute ischemic stroke. nti also has early-stage development programs for Alzheimer's and Huntington's ...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

...ic) has provided an update on XERECEPT(R). nti sold the worldwide rights and assets related to XERECEPT to Celtic in November 2005. nti is entitled to receive milestone payments upon the..., and if XERECEPT is approved for commercial sale, nti is also entitled to receive profit-sharing payment...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

...trial, which we expect to complete by mid-2009." nti also announced that it has amended its stockholder...ed under the plan. Conference Call Information nti will webcast its quarterly financial results and h... which there are few acceptable treatment options. nti also has early-stage development programs for Alzh...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...nex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's di...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...rate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine...diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's ...

Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008

...nex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's di...

Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine

...harmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, ...

Neurobiological Technologies' CEO to Retire on December 31, 2008

...s sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active nti director beyond my retirement." A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva...

Neurobiological Technologies Reports Third Quarter Financial Results

...ion. During the three months ended March 31, 2008, nti wrote-down the value of its auction rate securitie...anial hemorrhage." Conference Call Information nti will webcast its quarterly financial results and h...tients can be treated after the onset of a stroke. nti also has the right to receive royalty payments fro...

Neurobiological Technologies Sets Date for Third Quarter Financial Results

...e the time period that patients can be treated after the onset of a stroke. nti also has the right to receive royalty payments from sales of Namenda(R) (me...inical development for swelling associated with brain tumors. Additionally, nti has rights to two compounds in early-stage development for Alzheimer's and ...

Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine

...antine for the treatment of moderate-to-severe Alzheimer's disease during the quarter ended December 31, 2007. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, ...

Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens' Hospital

...30, 2008 of the royalties on sales of memantine in the third quarter of 2007 in the amount of $2,161,228. About Neurobiological Technologies, Inc. nti is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate...

Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine

...emantine for the treatment of moderate-to-severe Alzheimer's disease for the quarter ended September 30, 2007. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners. Paul E. Freiman, President and CEO of Neurob...

Neurobiological Technologies Sets Date for Research and Development Day

...estions about the R&D Development Day can be directed to Walter Kass, NTI Investor Counsel, 212-300-4708. About Neurobiological Technologies, Inc. nti is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate...

Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call

...lay number: 888-203-1112 (U.S. and Canada) / 719-457-0820 (international). Replay access code: 3898964. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies Sets Date for Second Quarter Financial Results

...lay number: 888-203-1112 (U.S. and Canada) / 719-457-0820 (international). Replay access code: 3898964. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board

...n advisor to the company and we are pleased that he has agreed to continue to be available to advise us." About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

... sale would be unlawful prior to registration or qualification under the securities laws of any such state. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split

...ates and receive new post-split certificates. Conference Call Information nti will web cast its year end financial results conference call on September 1...l), replay access code: 9278405. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and ...

Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq

...and which is expected to close after the above-referenced 30-day cure period expires on September 28, 2007. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A

...e PCR primers and molecular beacons were synthesized commercially (IDT Corporation, Coralville, IA). PCR primers were designed using Vector nti software (InforMax, North Bethesda, MD). The melting temperatures (T m ) of the primer and probe sequences were determined by Ol...
Other Tags
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
Other Contents